Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

Rhea-AI Summary

Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been selected for addition to the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical securities on the Nasdaq and is re-ranked annually through a modified capitalization-weighted methodology. Viracta focuses on precision oncology targeting virus-associated malignancies, with its investigational drug nanatinostat currently in trials for EBV-positive lymphoma and nasopharyngeal carcinoma.

Positive

• Inclusion in the Nasdaq Biotechnology Index may enhance visibility and attract institutional investors.
• Ongoing clinical trials for nanatinostat position the company in a growing sector of precision oncology targeting EBV-related cancers.

Negative

• None.

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs). More information about the NBI, including eligibility criteria, can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a registration-enabling Phase 2 clinical trial for EBV-positive (EBV⁺) lymphoma and a Phase 1b/2 trial in patients with EBV⁺ nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-be-added-to-the-nasdaq-biotechnology-index-301445981.html

SOURCE Viracta Therapeutics, Inc.

FAQ

What is the significance of Viracta being added to the Nasdaq Biotechnology Index?

Being added to the Nasdaq Biotechnology Index enhances Viracta's visibility and may attract more institutional investments.

When will Viracta be added to the Nasdaq Biotechnology Index?

Viracta will be added to the Nasdaq Biotechnology Index effective prior to market open on December 20, 2021.

What are the current clinical trials Viracta is conducting?

Viracta is conducting a Phase 2 clinical trial for EBV-positive lymphoma and a Phase 1b/2 trial for EBV-positive nasopharyngeal carcinoma with its drug nanatinostat.

What is the stock symbol for Viracta Therapeutics?

The stock symbol for Viracta Therapeutics is VIRX.